← Back

Wire · operational-macro

FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis

Published

19 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at neurologylive.com →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

The FDA approved cemdisiran (Livsayis), a quarterly subcutaneous siRNA treatment targeting complement C5, for adults in the US with AChR-antibody-positive generalized myasthenia gravis (gMG). Supported by the phase 3 NIMBLE trial showing significant efficacy and safety, Livsayis is the first siRNA therapy and provides the least frequent dosing among complement-targeted gMG treatments.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You just gained access to a newly approved siRNA therapy with quarterly dosing that could redefine treatment convenience for AChR-antibody-positive generalized myasthenia gravis. Prepare to engage neurologists keen on alternatives to frequent infusion therapies and explore patient adherence benefits.

◆ Coverage

1 source · 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalgmsiRNArare-diseasebiotechcomplement-inhibition